Key result
Left ventricular function evaluation (HR 0.83; 95% CI 0.705-0.976) and ACE inhibitor use (HR 0.77; 95% CI 0.655-0.905) were both associated with lower 3-year mortality in older heart failure patients.
Why the study?
Does left ventricular function evaluation and ACE inhibitor use improve survival in older Medicare beneficiaries hospitalized with heart failure?
Population
1,090 older Alabama Medicare beneficiaries discharged with a diagnosis of heart failure in 1994, mean age…
Comparison
Left ventricular function evaluation and… vs No left ventricular function evaluation and no…
Design
Cohort
Follow-up
3 years
Authors
Loading...
Supports LV evaluation and ACE inhibitor use in older HF; extends observational data to Medicare patients but leaves causality open for RCTs.
Cohort (n=1,090)
Does left ventricular function evaluation and ACE inhibitor use improve survival in older Medicare beneficiaries hospitalized with heart failure?
Hazard Ratio: 0.77 (95% CI 0.655–0.905)
Left ventricular function evaluation and ACE inhibitor use are associated with increased 3-year survival in older Medicare beneficiaries hospitalized with heart failure.
Ahmed et al. (2003) conducted a cohort in Heart failure (n=1,090). ACE inhibitor use and left ventricular function evaluation vs. No ACE inhibitor use / no evaluation was evaluated on 3-year mortality rate (HR 0.77, 95% CI 0.655-0.905). Left ventricular function evaluation (HR 0.83; 95% CI 0.705-0.976) and ACE inhibitor use (HR 0.77; 95% CI 0.655-0.905) were both associated with lower 3-year mortality in older heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: